12 results on '"Ottesen, Eric"'
Search Results
2. The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs.
- Author
-
Mathew, Christopher G, Bettis, Alison A, Chu, Brian K, English, Mike, Ottesen, Eric A, Bradley, Mark H, and Turner, Hugo C
- Subjects
PREVENTION of infectious disease transmission ,DISEASES ,ECONOMIC aspects of diseases ,DRUG administration ,ELEPHANTIASIS ,LABOR productivity ,LIFE expectancy ,MEDICAL care costs ,PEOPLE with disabilities ,PUBLIC health - Abstract
Background The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the goal of eliminating lymphatic filariasis (LF) as a public health problem by 2020. Despite considerable progress, the current prevalence is around 60% of the 2000 figure, with the deadline looming a year away. Consequently, there is a continued need for investment in both the mass drug administration (MDA) and morbidity management programs, and this paper aims to demonstrate that need by estimating the health and economic burdens of LF prior to MDA programs starting in GPELF areas. Methods A previously developed model was used to estimate the numbers of individuals infected and individuals with symptomatic disease, along with the attributable number of disability-adjusted life years (DALYs). The economic burden was calculated by quantifying the costs incurred by the health-care system in managing clinical cases, the patients' out-of-pocket costs, and their productivity costs. Results Prior to the MDA program, approximately 129 million people were infected with LF, of which 43 million had clinical disease, corresponding to a DALY burden of 5.25 million. The average annual economic burden per chronic case was US $115, the majority of which resulted from productivity costs. The total economic burden of LF was estimated at US $5.8 billion annually. Conclusions These results demonstrate the magnitude of the LF burden and highlight the continued need to support the GPELF. Patients with clinical disease bore the majority of the economic burden, but will not benefit much from the current MDA program, which is aimed at reducing transmission. This assessment further highlights the need to scale up morbidity management programs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
3. The Elimination of Neglected Tropical Diseases: A Case Study Exemplifying How Foreign Assistance Funding Can Be Catalytic in Reducing the Burden of Major Global Health Conditions.
- Author
-
Wainwright, Emily, Evans, Darin, Rotondo, Lisa, Pou, Bolivar, Yevstigneyeva, Violetta, Zoerhoff, Kathryn L, Ottesen, Eric A, and Reithinger, Richard
- Subjects
SCHISTOSOMIASIS prevention ,TRACHOMA prevention ,ONCHOCERCIASIS prevention ,GOVERNMENT agencies ,DRUG administration ,ELEPHANTIASIS ,ENDOWMENTS ,HELMINTHIASIS ,INTERNATIONAL relations ,PUBLIC health ,TROPICAL medicine ,WORLD health ,DISEASE eradication - Abstract
In 2006, following direct advocacy and published rationale, the US Agency for International Development (USAID) established a neglected tropical diseases (NTDs) program to support the scale-up of integrated platforms to target the elimination and control of 5 NTDs—lymphatic filariasis, trachoma, onchocerciasis, schistosomiasis, and soil-transmitted helminthiasis. By 2017, more than 2.3 billion NTD treatments had been delivered to at-risk populations in 25 countries, leveraging $19 billion in donated drugs—approximately $26 dollars in donated medicine per $1 spent by USAID. As a result, most of the supported countries are on track to achieve their elimination goals (for lymphatic filariasis and trachoma) by 2020 or 2021 and their control goals soon thereafter. Though "small" when compared to other global health initiatives, this investment proved to be catalytic, and indeed highlights how foreign assistance funding can be transformative, in reducing the burden of major global health conditions such as NTDs. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
4. Onchocerciasis: shifting the target from control to elimination requires a new first-step--elimination mapping.
- Author
-
Rebollo, Maria P., Zoure, Honorat, Ogoussan, Kisito, Sodahlon, Yao, Ottesen, Eric A., and Cantey, Paul T.
- Subjects
ONCHOCERCIASIS ,DISEASE eradication ,ONCHOCERCA volvulus ,DRUG administration - Abstract
The meaning of 'mapping' in relation to onchocerciasis has changed at least three times over the past 50 years as the programmatic goals and the assessment tools have changed. With the current goal being global elimination of Onchocerca volvulus (OV), all areas where OV might currently be transmitted and where mass drug administration (MDA) with ivermectin treatment has not been delivered previously must now be identified by careful, detailed 'elimination mapping' as either OV endemic or not, so that appropriate programmatic targets can be established. New tools and strategies for such elimination mapping have become available, though ongoing studies must still be completed to define agreed upon optimal diagnostic evaluation units, sampling strategies and serologic tools. With detailed guidance and technical support from the World Health Organization and with implementation and financial support from their global partners, the OV-endemic countries of Africa can soon complete their elimination mapping and then continue with MDA programmes to progressively achieve the same success in OV elimination as that already achieved by the growing list of formerly OV-endemic countries in the Americas. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Global Programme to Eliminate Lymphatic Filariasis: The Processes Underlying Programme Success.
- Author
-
Ichimori, Kazuyo, King, Jonathan D., Engels, Dirk, Yajima, Aya, Mikhailov, Alexei, Lammie, Patrick, and Ottesen, Eric A.
- Subjects
FILARIASIS ,FILARIAL worms ,TROPICAL medicine ,DRUG administration ,WORLD health ,TREATMENT programs - Abstract
The article discusses the Global Programme to Eliminate Lymphatic Filariasis (LF), a disease caused by filarial worms that affects over 1.39 billion people in 73 countries. The program aims to eliminate LF as a public health problem by 2020 through mass drug administration (MDA) and post-MDA surveillance. The World Health Organization's Global Programme to Eliminate Lymphatic Filariasis (GPELF) plays a crucial role in coordinating efforts and collaborating with other neglected tropical disease programs. The program is monitored by independent review groups and reports progress to the World Health Organization. [Extracted from the article]
- Published
- 2014
- Full Text
- View/download PDF
6. Progress and Impact of 13 Years of the Global Programme to Eliminate Lymphatic Filariasis on Reducing the Burden of Filarial Disease.
- Author
-
Ramaiah, K. D. and Ottesen, Eric A.
- Subjects
- *
FILARIASIS , *SYMPTOMS , *HYDROCELE , *DRUG administration , *LYMPHEDEMA - Abstract
Background: A Global Programme to Eliminate Lymphatic Filariasis was launched in 2000, with mass drug administration (MDA) as the core strategy of the programme. After completing 13 years of operations through 2012 and with MDA in place in 55 of 73 endemic countries, the impact of the MDA programme on microfilaraemia, hydrocele and lymphedema is in need of being assessed. Methodology/Principal findings: During 2000–2012, the MDA programme made remarkable achievements – a total of 6.37 billion treatments were offered and an estimated 4.45 billion treatments were consumed by the population living in endemic areas. Using a model based on empirical observations of the effects of treatment on clinical manifestations, it is estimated that 96.71 million LF cases, including 79.20 million microfilaria carriers, 18.73 million hydrocele cases and a minimum of 5.49 million lymphedema cases have been prevented or cured during this period. Consequently, the global prevalence of LF is calculated to have fallen by 59%, from 3.55% to 1.47%. The fall was highest for microfilaraemia prevalence (68%), followed by 49% in hydrocele prevalence and 25% in lymphedema prevalence. It is estimated that, currently, i.e. after 13 years of the MDA programme, there are still an estimated 67.88 million LF cases that include 36.45 million microfilaria carriers, 19.43 million hydrocele cases and 16.68 million lymphedema cases. Conclusions/Significance: The MDA programme has resulted in significant reduction of the LF burden. Extension of MDA to all at-risk countries and to all regions within those countries where MDA has not yet reached 100% geographic coverage is imperative to further reduce the number of microfilaraemia and chronic disease cases and to reach the global target of interrupting transmission of LF by 2020. Author Summary: The mass drug administration (MDA) programme to eliminate lymphatic filariasis (LF) was initiated in 2000. By the end of 2012, the programme was in place in 55 endemic countries. During these first 13 years (2000–2012) of programme implementation, 6.37 billion annual single dose anti-filarial treatments were offered and 4.45 billion doses were consumed by the target populations. This massive programme is estimated to have prevented or cured 96.71 million LF cases that include 79.20 million microfilaria carriers, 18.73 million hydrocele cases and a minimum of 5.49 million lymphedema cases, a 59% reduction of initial LF levels. It is further estimated that, currently, i.e. after 13 years of the MDA programme, 67.88 million LF cases remain, including 36.45 million microfilaria carriers, 19.43 million hydrocele cases and 16.68 million lymphedema cases. Progressive reduction in this burden is possible as the programme extends to the endemic countries and regions within endemic countries that have not yet been covered by the MDA programme, and if the morbidity management component of the programme can be effectively implemented. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
7. Transmission Assessment Surveys (TAS) to Define Endpoints for Lymphatic Filariasis Mass Drug Administration: A Multicenter Evaluation.
- Author
-
Chu, Brian K., Deming, Michael, Biritwum, Nana-Kwadwo, Bougma, Windtaré R., Dorkenoo, Améyo M., El-Setouhy, Maged, Fischer, Peter U., Gass, Katherine, Gonzalez de Peña, Manuel, Mercado-Hernandez, Leda, Kyelem, Dominique, Lammie, Patrick J., Flueckiger, Rebecca M., Mwingira, Upendo J., Noordin, Rahmah, Offei Owusu, Irene, Ottesen, Eric A., Pavluck, Alexandre, Pilotte, Nils, and Rao, Ramakrishna U.
- Subjects
FILARIASIS ,DRUG administration ,EPIDEMIOLOGY ,OPERATIONS research ,SAMPLE size (Statistics) - Abstract
Background: Lymphatic filariasis (LF) is targeted for global elimination through treatment of entire at-risk populations with repeated annual mass drug administration (MDA). Essential for program success is defining and confirming the appropriate endpoint for MDA when transmission is presumed to have reached a level low enough that it cannot be sustained even in the absence of drug intervention. Guidelines advanced by WHO call for a transmission assessment survey (TAS) to determine if MDA can be stopped within an LF evaluation unit (EU) after at least five effective rounds of annual treatment. To test the value and practicality of these guidelines, a multicenter operational research trial was undertaken in 11 countries covering various geographic and epidemiological settings. Methodology: The TAS was conducted twice in each EU with TAS-1 and TAS-2 approximately 24 months apart. Lot quality assurance sampling (LQAS) formed the basis of the TAS survey design but specific EU characteristics defined the survey site (school or community), eligible population (6–7 year olds or 1
st –2nd graders), survey type (systematic or cluster-sampling), target sample size, and critical cutoff (a statistically powered threshold below which transmission is expected to be no longer sustainable). The primary diagnostic tools were the immunochromatographic (ICT) test for W. bancrofti EUs and the BmR1 test (Brugia Rapid or PanLF) for Brugia spp. EUs. Principal Findings/Conclusions: In 10 of 11 EUs, the number of TAS-1 positive cases was below the critical cutoff, indicating that MDA could be stopped. The same results were found in the follow-up TAS-2, therefore, confirming the previous decision outcome. Sample sizes were highly sex and age-representative and closely matched the target value after factoring in estimates of non-participation. The TAS was determined to be a practical and effective evaluation tool for stopping MDA although its validity for longer-term post-MDA surveillance requires further investigation. Author Summary: Lymphatic filariasis (LF) is targeted for global elimination through a strategy of repeated annual mass drug administration (MDA) to entire at-risk populations. A transmission assessment survey (TAS) is designed to evaluate whether transmission of LF is presumed to have reached a level low enough that it cannot be sustained in the absence of drug intervention and, therefore, MDA can be stopped. This multicenter operational research trial examines the value and practicality of the TAS guidelines through its implementation in 11 countries of diverse geographical and epidemiologic profiles. The field experiences support the TAS survey design methodology with particular respect to school and cluster-based sampling strategies. We found that sample sizes were age and sex representative and met the target values after factoring in estimates of non-participation rates. In 10 of 11 countries, the TAS found the number of positive cases in the evaluation unit to be no more than the statistically powered critical threshold. These results were corroborated in a follow-up TAS approximately 24 months later. We conclude the TAS is a valuable and effective tool for stopping MDA but its utility for longer-term post-MDA surveillance needs further empirical evidence and may be best supported with complementary tools and methods. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
8. Predictive vs. Empiric Assessment of Schistosomiasis: Implications for Treatment Projections in Ghana.
- Author
-
Kabore, Achille, Biritwum, Nana-Kwadwo, Downs, Philip W., Soares Magalhaes, Ricardo J., Zhang, Yaobi, and Ottesen, Eric A.
- Subjects
SCHISTOSOMIASIS ,SCHISTOSOMA haematobium ,EDUCATIONAL surveys ,DRUG administration ,GEOLOGICAL statistics - Abstract
Background: Mapping the distribution of schistosomiasis is essential to determine where control programs should operate, but because it is impractical to assess infection prevalence in every potentially endemic community, model-based geostatistics (MBG) is increasingly being used to predict prevalence and determine intervention strategies. Methodology/Principal Findings: To assess the accuracy of MBG predictions for Schistosoma haematobium infection in Ghana, school surveys were evaluated at 79 sites to yield empiric prevalence values that could be compared with values derived from recently published MBG predictions. Based on these findings schools were categorized according to WHO guidelines so that practical implications of any differences could be determined. Using the mean predicted values alone, 21 of the 25 empirically determined 'high-risk' schools requiring yearly praziquantel would have been undertreated and almost 20% of the remaining schools would have been treated despite empirically-determined absence of infection – translating into 28% of the children in the 79 schools being undertreated and 12% receiving treatment in the absence of any demonstrated need. Conclusions/Significance: Using the current predictive map for Ghana as a spatial decision support tool by aggregating prevalence estimates to the district level was clearly not adequate for guiding the national program, but the alternative of assessing each school in potentially endemic areas of Ghana or elsewhere is not at all feasible; modelling must be a tool complementary to empiric assessments. Thus for practical usefulness, predictive risk mapping should not be thought of as a one-time exercise but must, as in the current study, be an iterative process that incorporates empiric testing and model refining to create updated versions that meet the needs of disease control operational managers. Author Summary: The challenge of accurately mapping schistosomiasis is a daunting one – particularly because of the highly focal distribution of the disease. Ideally, of course, each specific treatment area would be assessed for infection prevalence and then treated appropriately based on guidelines of the World Health Organization. In practice, however, this is not possible, and a variety of short-cutting techniques have been developed to meet these mapping needs, including geospatial predictive mapping. This paper assesses the accuracy of model-based geostatistics (MBG) predictions for determining treatments projections in Ghana by comparing previously published data using MBG predictions with empirically derived prevalence values for schistosomiasis from school surveys completed at 79 sites. We found that using predictive mapping alone would not have provided reliable information for mass drug administration (MDA) planning – resulting in overtreatment in some areas and most importantly under-treatment in areas that needed it most. Based on our findings, predictive risk mapping cannot be a one-time exercise but must instead be a process that incorporates empiric testing and model refining to create optimised spatial decision support tools that meet the needs of disease control operational managers. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
9. Antibody to the Filarial Antigen Wb123 Reflects Reduced Transmission and Decreased Exposure in Children Born following Single Mass Drug Administration (MDA).
- Author
-
Steel, Cathy, Kubofcik, Joseph, Ottesen, Eric A., and Nutman, Thomas B.
- Subjects
DRUG administration ,ANTIGENS ,IMMUNOGLOBULINS ,FILARIASIS ,FILARIAL worms - Abstract
Background: Antibody (Ab) to the Wuchereria bancrofti (Wb) infective larval (L3) antigen Wb123, using a Luciferase Immunoprecipitation System (LIPS) assay, has been shown to be a species-specific, early marker of infection developed for potential use as a surveillance tool following transmission interruption post mass drug administration. To examine its usefulness in a single filarial-endemic island assessed at two time points with markedly different levels of transmission, Ab to Wb123 was measured in sera collected from subjects from Mauke, Cook Islands in 1975 (no previous treatment) and 1992 (5 years after a one time island-wide treatment with diethylcarbamazine [DEC]). Findings: Between 1975 and 1992, Wb transmission decreased dramatically as evidenced by reduced prevalences of microfilariae (31% vs. 5%) and circulating Ag (CAg, 49% vs. 16%). Age specific prevalence analysis showed a dramatic reduction in Wb123 Ab positivity from 54% (25/46) in 1975 to 8% (3/38) in 1992 in children 1–5 years (p<0.0001), reflecting the effects of single-dose treatment five years earlier. By 1992, Wb123 Ab prevalence in children 6–10 years had fallen from 75% (42/56) in 1975 to 42% (33/79) consistent with a lower cumulative transmission potential. In the whole population, Wb123 seropositivity decreased from 86% to 60% between 1975 and 1992. In CAg+ subjects the levels of Wb123 Ab were indistinguishable between the 2 time points but differed in those who were CAg− (p<0.0001). In paired sample analysis, individuals who were CAg+ in 1975 but became CAg− in 1992 had significantly lower Ab levels in 1992 (p<0.0001), with 9/40 (23%) becoming seronegative for Wb123. Conclusions: The relationship between reduction in Wb123 Ab prevalence and the reduction of transmission, seen most clearly in young children, strongly advocates for the continuing assessment and rapid development of Wb123 as a surveillance tool to detect potential transmission of bancroftian filariasis in treated endemic areas. Author Summary: Lymphatic filariasis (LF) causes an enormous disease burden throughout the tropics and subtropics. The Global Programme to Eliminate Lymphatic Filariasis was begun in 2000 following the advent of large donations from drug companies for treating LF and the development of a rapid antigen assay for detection of infection. As more countries undergo mass drug administration (MDA), the driving need is for development of a highly sensitive and specific antibody assay for detecting ongoing exposure to vector-borne filaria following MDA. The target group for such surveillance is children born during or following MDA. Current assays, while sensitive, are not specific enough where non-LF filaria species are co-endemic. Recently, we developed an antibody assay based upon the highly specific larval antigen Wb123 using the Luciferase Immunoprecipitation System (LIPS). In the current study, we determined that the Wb123 LIPS assay detects a reduction in LF transmission on an endemic island following a one-time island wide MDA with diethylcarbamazine, with the most pronounced reduction in prevalence of antibody to Wb123 occurring in young children born just prior to and following this MDA. We propose that Wb123 can be an extremely useful surveillance tool following MDA and should be developed into a rapid test format. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
10. The Economic Benefits Resulting from the First 8 Years of the Global Programme to Eliminate Lymphatic Filariasis (2000-2007).
- Author
-
Chu, Brian K., Hooper, Pamela J., Bradley, Mark H., McFarland, Deborah A., and Ottesen, Eric A.
- Subjects
FILARIASIS ,LYMPHATIC diseases ,INTERNATIONAL cooperation on public health ,DRUG administration ,LYMPHEDEMA ,DISEASE prevalence ,COMMUNITY health services - Abstract
Background: Between 2000-2007, the Global Programme to Eliminate Lymphatic Filariasis (GPELF) delivered more than 1.9 billion treatments to nearly 600 million individuals via annual mass drug administration (MDA) of anti-filarial drugs (albendazole, ivermectin, diethylcarbamazine) to all at-risk for 4-6 years. Quantifying the resulting economic benefits of this significant achievement is important not only to justify the resources invested in the GPELF but also to more fully understand the Programme's overall impact on some of the poorest endemic populations. Methodology: To calculate the economic benefits, the number of clinical manifestations averted was first quantified and the savings associated with this disease prevention then analyzed in the context of direct treatment costs, indirect costs of lost-labor, and costs to the health system to care for affected individuals. Multiple data sources were reviewed, including published literature and databases from the World Health Organization, International Monetary Fund, and International Labour Organization. Principal Findings: An estimated US$21.8 billion of direct economic benefits will be gained over the lifetime of 31.4 million individuals treated during the first 8 years of the GPELF. Of this total, over US$2.3 billion is realized by the protection of nearly 3 million newborns and other individuals from acquiring lymphatic filariasis as a result of their being born into areas freed of LF transmission. Similarly, more than 28 million individuals already infected with LF benefit from GPELF's halting the progression of their disease, which results in an associated lifetime economic benefit of approximately US$19.5 billion. In addition to these economic benefits to at-risk individuals, decreased patient services associated with reduced LF morbidity saves the health systems of endemic countries approximately US$2.2 billion. Conclusions/Significance: MDA for LF offers significant economic benefits. Moreover, with favorable program implementation costs (largely a result of the sustained commitments of donated drugs from the pharmaceutical industry) it is clear that the economic rate of return of the GPELF is extremely high and that this Programme continues to prove itself an excellent investment in global health. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
11. Eliminating lymphatic filariasis.
- Author
-
Ichimori, Kazuyo and Ottesen, Eric A.
- Subjects
- *
FILARIASIS , *ETIOLOGY of diseases , *LYMPHEDEMA , *POVERTY , *DRUG administration , *COST effectiveness , *INFECTIOUS disease transmission - Published
- 2011
12. Initiating NTD programs targeting schistosomiasis and soil-transmitted helminthiasis in two provinces of the Democratic Republic of the Congo: Establishment of baseline prevalence for mass drug administration.
- Author
-
Kabore, Achille, Ibikounle, Moudachirou, Tougoue, Jean Jacques, Mupoyi, Sylvain, Ndombe, Martin, Shannon, Scott, Ottesen, Eric A., Mukunda, Faustin, and Awaca, Naomi
- Subjects
- *
SCHISTOSOMIASIS , *HELMINTHIASIS , *DRUG administration , *DISEASE prevalence , *PUBLIC health , *PARASITOLOGY , *HEALTH surveys , *INFECTIOUS disease transmission - Abstract
Background Schistosomiasis (SCH) and soil-transmitted helminthiasis (STH) are widely distributed in the Democratic Republic of the Congo (DRC) and constitute a serious public health problem. As recommended by the World Health Organization (WHO), before launching mass chemotherapy to control these diseases, parasitological surveys were conducted in sentinel sites in six health zones (HZs) in Bandundu and Maniema provinces. Baseline prevalence and intensity of infection for SCH and STH were determined to establish the appropriate treatment plan using Praziquantel (PZQ) and Albendazole (ALB). Methods Parasitological surveys were conducted from April to May 2015 in twenty-six selected sampling units (schools) for baseline mapping in six HZs: Fifty school children (25 females and 25 males) aged 9–15 years were randomly selected per sampling unit. A total of 1300 samples (urine and stool) were examined using haematuria dipsticks, parasite-egg filtration and the point-of-care Circulating Cathodic Antigen (POC-CCA) assay for urine samples and the Kato-Katz technique for stool specimens. Results Three species of schistosomes ( S. mansoni , S. haematobium and S. intercalatum ) and three groups of STH (hookworm, Ascaris and Trichuris ) were detected at variable prevalence and intensity among the schools, the HZs and the provinces. In Bandundu, no SCH was detected by either Kato-Katz or the POC-CCA technique, despite a high prevalence of STH with 68% and 80% at Kiri and Pendjua HZs, respectively. In Maniema, intestinal schistosomiasis was detected by both Kato-Katz and POC-CCA with an average prevalence by Kato-Katz of 32.8% and by POC-CCA of 42.1%. Comparative studies confirmed the greater sensitivity (and operational feasibility) of the POC-CCA test on urine compared to Kato-Katz examination of stool for diagnosing intestinal schistosomiasis even in areas of comparatively light infections. STH was widely distributed and present in all HZs with a mean prevalence (95% CI) of 59.62% (46.00–65.00%). The prevalence of hookworm, roundworm and whipworm were 51.62% (32.40%–71.50%), 15.77% (0.50%–39.60%) and 13.46 (0.50%–33.20%), respectively. Conclusion This study provided the evidence base for implementing programs targeting SCH and STH in these Health Zones. Observations also reinforce the operational value and feasibility of the POC-CCA test to detect S. mansoni and, for the first time, S. intercalatum infections in a routine NTD program setting. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.